The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms
Public ClinicalTrials.gov record NCT00401245. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS SR in Women With Vasomotor Symptoms Associated With Menopause: The PRIMMUS (PRIstiq for Managing Menopause and Understanding Symptoms) Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Desvenlafaxine succinate (DVS SR) is a serotonin and norepinephrine reuptake inhibitor (SNRI). It is a nonhormonal option for the treatment of Vasomotor Symptoms (VMS) associated with menopause. Nausea is the most common adverse event that is observed in clinical studies and is the main reason for discontinuation during the first week of therapy. Other adverse events (headache, nausea, and dizziness) associated with DVS SR have been noted to occur when subjects abruptly discontinue the medication. The purpose of this study is to evaluate several titration and tapering regimens of DVS SR to ensure a better tolerability profile at the start and completion of treatment. In addition, this study will provide a long posttreatment follow-up to assess any symptoms after treatment is discontinued.
Study identification
- NCT ID
- NCT00401245
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 500 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2006 (Type not available)
- Primary completion
- Jan 2008 (Actual)
- Completion
- Jan 2008 (Actual)
- Last update posted
- Oct 26, 2011
2006 – 2008
United States locations
- U.S. sites
- 55
- U.S. states
- 26
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Tucson | Arizona | 85710 | — |
| Pfizer Investigational Site | Tucson | Arizona | 85715 | — |
| Pfizer Investigational Site | Beverly Hills | California | 90211 | — |
| Pfizer Investigational Site | Encinitas | California | 92024 | — |
| Pfizer Investigational Site | Foothill Ranch | California | 92610 | — |
| Pfizer Investigational Site | San Diego | California | 92108 | — |
| Pfizer Investigational Site | San Diego | California | 92123 | — |
| Pfizer Investigational Site | Upland | California | 91786 | — |
| Pfizer Investigational Site | Denver | Colorado | 80218 | — |
| Pfizer Investigational Site | Longmont | Colorado | 80501 | — |
| Pfizer Investigational Site | Clearwater | Florida | 33761 | — |
| Pfizer Investigational Site | Crystal River | Florida | 34429 | — |
| Pfizer Investigational Site | DeLand | Florida | 32720 | — |
| Pfizer Investigational Site | Gainesville | Florida | 32606 | — |
| Pfizer Investigational Site | Lake Worth | Florida | 33461 | — |
| Pfizer Investigational Site | Miami | Florida | 33136 | — |
| Pfizer Investigational Site | Miami | Florida | 33143 | — |
| Pfizer Investigational Site | Miami | Florida | 33169 | — |
| Pfizer Investigational Site | Palm Harbor | Florida | 34684 | — |
| Pfizer Investigational Site | Tampa | Florida | 33606 | — |
| Pfizer Investigational Site | Idaho Falls | Idaho | 83404 | — |
| Pfizer Investigational Site | Champaign | Illinois | 61820 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60612 | — |
| Pfizer Investigational Site | South Bend | Indiana | 46601 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40536 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40291 | — |
| Pfizer Investigational Site | Metairie | Louisiana | 70002 | — |
| Pfizer Investigational Site | Metairie | Louisiana | 70006 | — |
| Pfizer Investigational Site | Canton | Michigan | 48187 | — |
| Pfizer Investigational Site | Ypsilanti | Michigan | 48197 | — |
| Pfizer Investigational Site | Billings | Montana | 59101 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68131-2197 | — |
| Pfizer Investigational Site | Las Vegas | Nevada | 89128 | — |
| Pfizer Investigational Site | Lebanon | New Hampshire | 03755 | — |
| Pfizer Investigational Site | New Brunswick | New Jersey | 08901 | — |
| Pfizer Investigational Site | Albuquerque | New Mexico | 87106 | — |
| Pfizer Investigational Site | Albuquerque | New Mexico | 87131 | — |
| Pfizer Investigational Site | New York | New York | 10032 | — |
| Pfizer Investigational Site | Chapel Hill | North Carolina | 27514 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28209 | — |
| Pfizer Investigational Site | Winston-Salem | North Carolina | 27103-4005 | — |
| Pfizer Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| Pfizer Investigational Site | Bismarck | North Dakota | 58501 | — |
| Pfizer Investigational Site | Fargo | North Dakota | 58104 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44122 | — |
| Pfizer Investigational Site | Eugene | Oregon | 97401 | — |
| Pfizer Investigational Site | Pittsburgh | Pennsylvania | 15206 | — |
| Pfizer Investigational Site | Watertown | South Dakota | 57201 | — |
| Pfizer Investigational Site | Carrollton | Texas | 75006 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
| Pfizer Investigational Site | Hurst | Texas | 76054 | — |
| Pfizer Investigational Site | Midland | Texas | 79705 | — |
| Pfizer Investigational Site | Norfolk | Virginia | 23502 | — |
| Pfizer Investigational Site | Norfolk | Virginia | 23507 | — |
| Pfizer Investigational Site | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00401245, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 26, 2011 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00401245 live on ClinicalTrials.gov.